State Street Cuts Myriad Genetics Stake to 5.0%
Ticker: MYGN · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 899923
| Field | Detail |
|---|---|
| Company | Myriad Genetics Inc (MYGN) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | medium |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, stake-reduction, amended-filing
TL;DR
**State Street just trimmed its Myriad Genetics stake to 5.0%, watch for potential stock price reaction.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 24, 2024, disclosing its ownership of 5.0% of Myriad Genetics Inc.'s common stock as of December 31, 2023. This represents a decrease from previous holdings, indicating State Street has reduced its stake in Myriad Genetics. For investors, this matters because a large institutional investor reducing its position could signal a lack of confidence in the company's future prospects, potentially influencing other investors' decisions and the stock price.
Why It Matters
A significant institutional investor like State Street reducing its ownership in Myriad Genetics could be interpreted as a bearish signal, potentially impacting investor sentiment and the stock's performance.
Risk Assessment
Risk Level: medium — The reduction in a major institutional holding could indicate a perceived increase in risk or a less favorable outlook for Myriad Genetics by State Street.
Analyst Insight
A smart investor would investigate the reasons behind State Street's reduced stake in Myriad Genetics Inc. and consider if this signals a broader negative outlook for the company or its sector before making any investment decisions.
Key Numbers
- 5.0% — Percentage of Class Owned (State Street Corporation's ownership of Myriad Genetics Inc. common stock as of December 31, 2023.)
- 0000093751-24-000181 — Accession Number (Unique identifier for this specific SEC filing.)
Key Players & Entities
- State Street Corporation (company) — the reporting person who filed the SC 13G/A
- Myriad Genetics Inc. (company) — the issuer of the common stock
- 5.0% (dollar_amount) — the percentage of Myriad Genetics' common stock owned by State Street Corporation
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- Myriad Genetics Inc.'s stock price may experience downward pressure due to State Street's reduced stake. (Myriad Genetics Inc.) — medium confidence, target: Q1 2024
- Other institutional investors might re-evaluate their positions in Myriad Genetics Inc. following this disclosure. (Myriad Genetics Inc.) — medium confidence, target: Q1 2024
FAQ
What is the primary purpose of this SC 13G/A filing by State Street Corporation?
The primary purpose of this SC 13G/A filing is for State Street Corporation to disclose its beneficial ownership of 5.0% of Myriad Genetics Inc.'s common stock as of December 31, 2023, as an amendment to a previous filing, under Rule 13D-1(B).
Who is the 'issuer' of the securities mentioned in this filing?
The 'issuer' of the securities is MYRIAD GENETICS INC, with the title of class of securities being 'COMMON STOCK' and CUSIP number 62855J104.
What was the 'date of event' that triggered this filing?
The 'date of event which requires filing of this statement' was December 31, 2023.
What is the CUSIP number for Myriad Genetics Inc.'s common stock?
The CUSIP number for Myriad Genetics Inc.'s common stock is 62855J104, as stated on the cover page of the filing.
Under which specific SEC rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13D-1(B), as indicated by the 'X' next to 'RULE 13D-1 (B)' on the first page of the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding MYRIAD GENETICS INC (MYGN).